source
- Agios halts development of sickle cell drug tebapivat after mid-stage trial failureAgios announced it will stop developing tebapivat for sickle cell disease after a mid-stage trial did not meet expectations. The drug, a next-generation pyruvate kinase activator related to the ap…
- Dimension raises $800 million for third fund to boost AI-driven biotech venturesDimension, a venture capital firm focused on the intersection of technology and biotech, announced the closing of its largest fund to date, raising $800 million for its third fund, called Dimension…